Vermittlung. Die 1950er Jahre

2014

Metabolic syndrome (MetS) is a cluster of symptoms seen in type 2 diabetes mellitus, cardiovascular diseases, hypertension and obesity. Insulin resistance is a major component of MetS and is thus the key to cure and prevent any related illnesses. The treatment of type 2 diabetes mellitus in Traditional Chinese Medicine is focused on replenishing Yin (fluid) and evacuating fire (heat) from the body and, depending on the symptoms it can also be focused on replenishing the yang. We study how the Kidney tonifying preparations (Liuwei dihuang wan-LW and Bawei dihuang wan-BW) affect osteocalcin levels to treat insulin resistance. We induced insulin resistance in Rats by a large dose of Dexamethasone 1 g/kg/alternate days (DXM) and simultaneously administered the LW low dose 1 g/kg, LW high dose 4 g/kg, BW low dose 1 g/kg, BW high dose 4 g/kg and Simvastatin 20 mg/kg (positive control). After a 2hr oral glucose tolerance test, blood was drawn for serum analysis of lipids, osteocalcin, adiponectin and leptin. Our results showed that LW and BW might act through increasing insulin sensitizing hormones-osteocalcin and adiponectin, and reducing hormones increased in obesity like leptin. The increase in insulin sensitizing hormones might be able to reduce the measures of insulin sensitivity. LW and BW might be unable to control lipid dysregulation in DXM induced insulin resistance.

Journal of Ethnopharmacology, 2012

Ethnopharmacological relevance: Traditional Chinese medicine (TCM) formulas have been widely used in China since ancient times to treat certain diseases (e.g., phlegm, dampness and blood stasis). Recently, the effects of these medicines have been increasingly demonstrated to be helpful for hyperlipidemic patients. Aim of the study: This manuscript aims to describe the scientific evidence for the efficacy of TCM and attempts to identify potential TCM formulas for treating hyperlipidemia. Materials and methods: TCM formulas approved by the State Food and Drug Administration of China (SFDA) were sourced from the official SFDA website (http://www.sda.gov.cn/). Human and animal evidence for the hypolipidemic effects of herbs from TCM formulas were reviewed via the Internet (Elsevier, ACS, Wiley Online Library, SpringerLink, PubMed, Web of Science, CNKI, Baidu, and Google) and libraries up to October 31, 2011. Results: More than 50 TCM formulas have been used to treat hyperlipidemia. These herbs can primarily be grouped into three categories: (1) herbs promoting excretions, generally by reducing food retention, enhancing purgative effects, and promoting diuresis and choleretic effects, e.g., Fructus Crataegi ( ), Radix Polygoni Multiflori ( ), Semen Cassiae ( ), and Radix et Rhizoma Rhei ( ), Rhizoma alismatis ( ), and Herba Artemisiae Scopariae ( ); (2) herbs acting on the cardiovascular system, generally by improving blood circulation based on TCM theories, e.g., Radix Salviae Miltiorrhizae ( ), Radix Puerariae ( ), Rhizoma Chuanxiong ( ), Flos Carthami ( ), and Folium Nelumbinis ( ); and (3) herbs that have tonic effects, e.g., Fructus Lycii ( ), Radix Ginseng ( ), and Radix Astragali (

Journal of Life Sciences, 2013

patients with Secondary Dyslipidemia and CKD (Chronic Kidney Disease) (females: 387; males: 717; aged: 70 ± 11 years), were given Dif1stat ® with diet to evaluate efficacy and safety. The study lasted two years. Patients were assigned to three groups (A, B, C) based upon basal renal function. Group A consisted of 180 patients with GFR (glomerular filtration rate) of 67 ± 16ml/min/m². TC (Total-Cholesterol) (-31%), LDLC (LDL-Cholesterol) (-42%), TG (triglycerides) (-36.8%) levels, and nonHDLC (non HDLC holesterol) (-41%) and TC/HDLC ratio (-40%) were significantly reduced (P < 0001). GFR (+2.5%) increased significantly. No significant changes were observed in HDLC (+13%). Group B was of 744 patients, 69% (males: 514), 31% (females: 230) (median age: 70 ± 13 years), and moderate stage III CKD (GFR: 38 ± 12 mL/min/1.73m²). After 24 months the change of HDLC (+3.5%) was not significant, while TC (-27%), TG (-32%), LDLC (-33%), non-HDLC (33.4%), TC/HDLC (-30%), and GFR (+2.1%) were st...

Journal of Clinical Lipidology, 2014

Background: Xuezhikang (XZK) is an extract of fermented red yeast rice that has lipidlowering properties.

International journal of scientific research, 2020

INTRODUCTION: One of the important cardiovascular risk factors responsible for cardiovascular disease and the rapid progression of chronic kidney disease (CKD) to end-stage renal disease is Dyslipidaemia. An important aspect ofthe reduction of cardiovascular complications and retardation ofthe progression of CKD is early detection and management of dyslipidemia. The leading cause of hospitalization and mortality in patients with chronic kidney disease is

Journal of Atherosclerosis and Thrombosis, 2020

The official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases Correspondence tic and international, of the importance of hyperlipidemia treatment. Based on their findings, the Ministry compiled a "Guideline for Clinical Evaluation Methodology for Antihyperlipidemic Drugs (January 05, 1988, Pharmaceutical Notification No. 1-1)." This guideline presented the general procedures for the planning, implementation, evaluation, and other specifics of clinical studies in order to evaluate the clinical efficacy of novel (oral) antihyperlipidemic drugs. Hyperlipidemia has been identified to cause several health disorders such as acute pancreatitis in

Frontiers in endocrinology, 2024

Background: Diabetic kidney disease (DKD) has become the leading cause of kidney failure, causing a significant socioeconomic burden worldwide. The usual care for DKD fails to achieve satisfactory effects in delaying the persistent loss of renal function. A Chinese herbal medicine, Tangshen Qushi Formula (TQF), showed preliminary clinical benefits with a sound safety profile for people with stage 2-4 DKD. We present the protocol of an ongoing clinical trial investigating the feasibility, efficacy, and safety of TQF compared to placebo in delaying the progressive decline of renal function for people with stage 2-4 DKD. Methods: A mixed methods research design will be used in this study. A randomized, double-blind, placebo-controlled pilot trial will evaluate the feasibility, efficacy, and safety of TQF compared to placebo on kidney function for people with stage 2-4 DKD. An embedded semi-structured interview will explore the acceptability of TQF granules and trial procedures from the participant's perspective. Sixty eligible participants with stage 2-4 DKD will be randomly allocated to the treatment group (TQF plus usual care) or the control group (TQF placebo plus usual care) at a 1:1 ratio for 48-week treatment and 12week follow-up. Participants will be assessed every 12 weeks. The feasibility will be assessed as the primary outcome. The changes in the estimated glomerular filtration rate, urinary protein/albumin, renal function, glycemic and lipid markers, renal composite endpoint events, and dampness syndrome of Chinese medicine will be assessed as the efficacy outcomes. Safety outcomes such as liver function, serum potassium, and adverse events will also be evaluated. The data and safety monitoring board will be responsible for the participants' benefits, the data's Frontiers in Endocrinology frontiersin.org 01

Biology, Engineering, Medicine and Science Reports, 2018

For coronary artery disease (CAD), it is generally accepted that prevention is better than cure. Cessation of cigarette smoking, habitual alcohol ingestion, changing sedentary life habits, skipping intake of processed or dairy foods, regular exercise can prevent people for being victimized by CAD. If taking all possible efforts described above, someone is getting ill, then come on to take Vitamin B 3 (Niacin) 2 grams daily and kalwanji or Nigella sativa. This study was conducted at National hospital, Lahore from 24 January 2016 to June 2016. It was single blind placebo-controlled study approved by ethics committee, National Hospital, Lahore. Ninety hyperlipidemic male/female patients age range from 22 to 60 years were selected from cardiology and medical wards of the hospital. They were divided in three groups, one at placebo therapy, another on Kalonji and third one on Vitamin B 3. After one and half month, significant changes (p value ranging from <0.05 to <0.001) were observed in their LDL and HDL-cholesterol as compared to pre and post-treatment values of placebo group. Conclusion of the study was to recommend use of herbal medicine and Vitamin B 3 for prevention of any heart diseases with good patient compliance.

Asrar Mohammed Al-Towerqi

Introduction: Dyslipidemia mainly refers to a disbalance of any form of lipid in the body. Any disbalance of lipid in the body puts the body at a higher risk of coronary and peripheral artery diseases. With the discovery of statins, there has been a huge revolution in the treatment of dyslipidemias. They have shown evidence of reduced levels of LDL with statin leading to a reduction in evidence of CVD. Aim of work: This review aims at discussing the various therapies and new management strategies developed for managing dyslipidemias associated with CVD or Chronic kidney diseases. Methodology: The review is a comprehensive research of PUBMED, Google Scholar, and WHO official page from the year 2010 to 2021 Conclusion: Dyslipidemias tend to increase the patients' risk for major cardiovascular events, which can lead to a higher mortality rate in patients with existing cardiac or kidney disorders. There has been an increased interest in the treatment of dyslipidemias, and various genetic therapies and novel medication, including plant-based proteins, have shown a major breakthrough in the management of dyslipidemias. These novel therapies have proven to be a good adjunct to conventional treatment strategies and hence should be tested more thoroughly. Keywords: Dyslipidemias, Cardiovascular disease, Apolipoproteins, Chronic kidney disease.

Media Penelitian dan Pengembangan Kesehatan, 2021

Epidemiological studies report that patients with chronic kidney disease (CKD) have a higher risk of mortality from cardiovascular disease than the general population. Previous studies have shown that dyslipidemia is thought to play a role in the development of atherosclerosis in patients with CKD. Dyslipidemia is known to be common in CKD patient population, but shows a diverse patterns in various CKD patient populations. This study aimed to analyze the lipid profile and lipid ratio in CKD patients at Dr. Soetomo Hospital Surabaya for the period 2016-2017. This cross-sectional study was conducted through retrospective observation of the medical records of CKD patient at the Kidney-Hypertension Polyclinic of Dr. Soetomo Hospital Surabaya in the 2016-2017 period. A total of 68 research subjects were analyed in this study. Most of the study subjects were male (68%) and the median age was 54 years. Almost 70% of the study subjects had CKD stage 5. Increased levels of total cholesterol ...